Health

Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.

Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

The dental technology developer’s proposed listing on the New York Stock Exchange would mark an exit for Henry Crown and Company.

The Ariad Pharmaceuticals-backed cancer therapeutics developer floated at the top of its range following $120m in venture funding.

Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.

Lithium mining process developer Lilac completed its series B round, which received backing from a several corporates. A sizeable round like this has been somewhat rare to see from the mining space, which has been so far somewhat neglected by corporates.

McKesson Ventures has returned to back a $40m round for Lightship, having co-led a $20m series B last year.

Amdocs and Comcast contributed to deep learning software provider Neural Magic's $30m series A round while packaging producer Creapaper completed a series B featuring Ranpak.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

SoftBank Vision Fund 2 led autistic childcare platform developer Elemy’s latest round, which valued it at $1.15bn.

Prosus Ventures has returned to back an equity and debt round for the homecare management platform developer secured at a $1.25bn valuation.